

FACULTY/PRESENTER DISCLOSURE

Faculty

DR. ROBERT HEGELE

Relationships with commercial interests:

- **Member of Advisory Board:** Abbott, Amgen, Boston Heart, Pfizer
- **Speakers Bureau:** Aegerion, Amgen, Pfizer, Sanofi
- **Grant/Honoraria:** HSFO, CIHR, Aegerion, Eli Lilly, Acasti, Amen, Pfizer, Sanofi, Cerenis, Ionis
- **Clinical Trials:** Pfizer, Sanofi, Amgen, Eli Lilly, Merck
- **Other:** none

DISCLOSURE OF COMMERCIAL SUPPORT

This program has received financial support from Amgen in the form of an educational grant.

This program has received in-kind support from Amgen in the form of logistical support.

Potential for conflict(s) of interest:

- Rob Hegele has received payment/funding from Amgen whose product is being discussed in this program.
- Amgen developed a product that will be discussed in this program:
Evolocumab/Repatha

MITIGATING POTENTIAL BIAS

- All content has been reviewed by a physician steering committee and the College of Family Physicians Canada
- All data has been sourced from evidence that is clinically accepted
- All support used in justification of patient care recommendations conform to generally accepted standards